Uncategorized
OASIS: Single Jetrea injection results in long-term resolution of vitreomacular adhesion
LAS VEGAS — A single intravitreal injection of 0.125 mg of ocriplasmin can result in long-term resolution of vitreomacular adhesion, according to a presentation here. At the American Academy of Ophthalmology annual meeting, Peter K. Kaiser, MD, presented results from the OASIS study evaluating a single injection of Jetrea (ocriplasmin, Thrombogenics) in patients with vitreomacular adhesion (VMA), including macular hole, and vitreomacular traction (VMT) at 24 months.